Evaluation Tests for Tablets and Capsules: A Review of Solid Oral Dosage Forms

The Enduring Importance of Solid Oral Dosage Forms

Solid oral dosage forms, such as tablets and capsules, are the most prevalent and widely utilized drug delivery systems in the global pharmaceutical market. They constitute over 70% of all formulations dispensed, a testament to their widespread acceptance and utility^4–6. Their popularity is not accidental; these forms offer unparalleled convenience for patients, are cost-effective to produce, easy to administer, and simple to transport. A significant advantage of tablets is their versatility, which allows formulators to create a variety of release profiles, including immediate, delayed, and sustained-release versions. Capsules, on the other hand, excel at masking the unpleasant taste of an active pharmaceutical ingredient (API)^7,8, protecting sensitive drugs from environmental factors like light and moisture, and delivering both powders and liquids with high dose precision. The development and rigorous evaluation of these dosage forms are foundational to modern pharmaceutical science, ensuring they are not only effective but also safe for patient consumption

A Historical Perspective and Market Dominance

The history of solid oral dosage forms dates back centuries, with ancient civilizations using compressed herbal powders. However, the modern tablet, as we know it, emerged in the mid-19th century with the invention of the tablet compression machine. This innovation revolutionized medicine by standardizing drug delivery and enabling mass production. Similarly, the development of gelatin capsules provided a more palatable alternative for bitter or foul-tasting medicines^8,9. These inventions paved the way for the pharmaceutical industry to grow from an apothecary-based model to a large-scale, industrial one.Today, tablets and capsules dominate the market due to their unique balance of efficacy, safety, and manufacturing efficiency^4,5. They are the go-to choice for a vast range of therapeutic areas, from over-the-counter pain relievers to life-saving prescription medications. Their market share continues to grow, driven by patient preference and continuous advancements in formulation science. This dominance, however, places a critical emphasis on robust quality control and evaluation to uphold public health standards.

Tablets vs. Capsules: A Comparative Overview

Although they are both solid oral dosage forms, tablets and capsules have distinct 

A tablet is a solid preparation containing one or more APIs, which are compacted with excipients into a specific shape. The manufacturing process involves pre-compression evaluation of the powder blend for properties like

flowability and compressibility, followed by post-compression tests on the finished product. Key post-compression tests for tablets include

hardness (crushing strength) and friability, which measure the tablet's resistance to breaking or chipping.

A capsule, conversely, is a unit-dose form where the drug is enclosed within a shell, typically made of gelatin or hydroxypropyl methylcellulose (HPMC). For capsules, evaluation focuses on the unique challenges posed by the shell and its contents. Shell-related issues such as moisture sensitivity, brittleness, and cross-linking are critical considerations¹⁶. Consequently, specific tests like moisture permeation and mechanical strength are vital for ensuring capsule integrity.

Despite these differences, tablets and capsules share several core evaluation tests, including

weight variation, content uniformity, disintegration, and dissolution. These shared tests are crucial for verifying that each dosage unit delivers the correct amount of drug at the proper rate.

The Critical Need for Evaluation and Quality Control

The evaluation of solid oral dosage forms is a scientific imperative, not merely a regulatory formality. A failure to perform these tests can lead to severe clinical outcomes, such as under-dosing, which can result in therapeutic failure, or over-dosing, which may cause adverse effects. For instance, a tablet with poor compression might suffer from

capping or lamination, where the top or bottom of the tablet separates from the main body. Similarly, improper storage can lead to

brittleness or cross-linking in capsule shells, affecting their stability and drug release¹⁰.

Systematic quality control ensures that every tablet and capsule is manufactured to a consistent standard, ensuring

dose accuracy, predictable drug performance, and patient safety. These tests are also instrumental in streamlining the scale-up process from a laboratory setting to commercial production, minimizing waste and preventing costly regulatory delays.

Regulatory Requirements and Modern Advances

The standards for evaluating tablets and capsules are globally harmonized by official pharmacopeias, including the

United States Pharmacopeia (USP), British Pharmacopoeia (BP), and Indian Pharmacopoeia (IP). These pharmacopeias provide detailed test procedures, acceptable limits, and criteria for various dosage forms. Additionally, international guidelines from the

International Council for Harmonisation (ICH), such as ICH Q6A, Q8, and Q10, provide a framework for a scientifically justified and risk-based approach to quality control^11–14.

While traditional tests remain the foundation of quality control, modern technology is revolutionizing the field.

Process Analytical Technology (PAT), Near-Infrared (NIR) spectroscopy, and Raman spectroscopy enable real-time, non-destructive monitoring of critical quality attributes during the manufacturing process^10,15. This shift from end-product testing to in-process control enhances efficiency and ensures a higher level of product quality.

The concept of in-vitro/in-vivo correlation (IVIVC) is also advancing, allowing formulators to predict a drug's absorption in the body based on in-vitro dissolution data, thereby reducing the need for extensive clinical trials. This review aims to consolidate and compare these various evaluation methods, providing a comprehensive guide for students, formulators, and researchers¹⁶.

2. Methodology of the Review

This review was compiled through a comprehensive and systematic literature search to ensure the inclusion of all critical evaluation parameters for solid oral dosage forms (tablets and capsules).

2.1 Literature Sources

Relevant information was meticulously gathered from a variety of authoritative sources:

• Pharmacopeial standards: This included official guidelines from major international pharmacopeias, such as the United States Pharmacopeia (USP) , the

British Pharmacopoeia (BP) , and the

Indian Pharmacopoeia (IP).

• Scientific journals: A wide range of scientific journals indexed in databases like PubMed, Scopus, ScienceDirect, and Google Scholar were reviewed.
• Reference textbooks: Key information was also sourced from foundational pharmaceutics textbooks, including Aulton's Pharmaceutics and Lachman's Theory and Practice of Industrial Pharmacy^3,7,9,17.
• Regulatory guidelines: Important guidelines from global bodies, such as the International Council for Harmonisation (ICH) and the World Health Organization (WHO), were also referenced^1,8,13,14.

The search used specific keywords to ensure a thorough collection of relevant data. These keywords included "tablet evaluation tests," "capsule evaluation tests," "pre-compression parameters," "post-compression quality control," "dissolution testing," "disintegration studies," "friability," "weight variation," "content uniformity," "stability testing," and "bioavailability".

2.2 Inclusion and Exclusion Criteria

To maintain the quality and focus of the review, specific criteria were applied during the selection of articles and guidelines.

• Inclusion: Articles and guidelines were included if they discussed evaluation parameters, techniques, equipment, comparative analysis of tablets and capsules, and updated pharmacopeial standards from the period of 2000-2024.
• Exclusion: Studies were excluded if they were not related to oral dosage forms, were outdated references from before the year 2000 (unless they were historically significant), or were not peer-reviewed data.

2.3 Data Organization

The collected information was systematically classified to provide a structured and comprehensive overview. The data was organized into the following key sections:

• Tablet Evaluation Tests
  • Pre-compression parameters
  • Post-compression parameters
  • Stability and dissolution studies
  • Advanced characterization tools
• Capsule Evaluation Tests
  • Shell properties and integrity
  • Weight variation and content uniformity
  • Disintegration and dissolution studies
  • Stability and packaging considerations
• Comparative Analysis of evaluation approaches for tablets versus capsules.

To enhance clarity, tables, figures, and flow diagrams were incorporated to visually represent the evaluation procedures. Each section of the review is supported by references to official pharmacopeial standards and relevant scientific studies.

2.4 Aim of the Review

The primary aim of this review is to consolidate and compare the various evaluation tests for tablets and capsules. By highlighting both their similarities and differences, while also integrating modern advancements, this review seeks to provide a valuable resource for researchers, formulators, and students in the field. It is designed to foster a deeper understanding of the scientific and regulatory aspects of quality control for solid oral dosage forms.

3. Evaluation Tests for Tablets

Tablets are the most widely used solid oral dosage form due to their ease of administration, accurate dosing, stability, and cost-effectiveness. However, to guarantee their quality, safety, and efficacy, tablets must undergo a series of systematic evaluation tests both during the formulation phase and after compression. These tests can be broadly categorized into several key areas: pre-compression parameters, post-compression parameters, in-vitro performance tests, and advanced characterization.

3.1 Pre-Compression Parameters

These tests are crucial for assessing the characteristics of the powder blend or granules before they are compressed into a tablet. Poor flow properties in the powder can lead to significant problems during manufacturing, such as weight variation, inconsistent hardness, or sticking to the tablet press, which ultimately compromises the quality of the final product.

3.1.1 Angle of Repose

The angle of repose measures the flowability of a powder. It is defined as the maximum angle formed between the surface of a pile of granules or powder and the horizontal plane. This angle is determined by allowing the powder to flow through a funnel onto a flat surface, and it is calculated from the height.

(h) and radius (r) of the resulting cone. A lower angle of repose indicates better flow properties, while a higher angle suggests poor flow^4,6.

3.1.2 Bulk Density and Tapped Density

These tests provide insights into the packing and compressibility of the powder.

Bulk density (BD) is the mass of the powder divided by its bulk volume, measured by simply pouring the powder into a graduated cylinder.

Tapped density (TD) is determined after mechanically tapping the container until the powder volume no longer changes. These values are used to calculate the compressibility indices of the powder^4,6.

3.1.3 Carr's Index (Compressibility Index)

Carr's Index is a measure of a powder's flowability and compressibility, derived from its bulk and tapped densities. It's calculated using the formula: CI = 100 × (ρT - ρB) / ρT.

. A lower index indicates better flow characteristics, with values below 10% considered excellent^3,4.

3.1.4 Hausner's Ratio

Similar to Carr's Index, Hausner's Ratio is another indicator of a powder's flowability. It is calculated as the ratio of tapped density to bulk density (HR=TD\BD)^3,4.

 A value closer to 1.0 indicates excellent flow, while values above 1.25 suggest poor flow.

3.1.5 Moisture Content

The moisture content of the powder blend is critical, as high moisture can lead to clumping, microbial growth, and poor compressibility during tableting. It is typically determined using a moisture analyzer or by a Loss on Drying (LOD) method.

3.2 Post-Compression Parameters

Once tablets are compressed, a series of quality control tests are performed to ensure their uniformity, strength, and patient acceptability.

3.2.1 General Appearance

The appearance of a tablet is the first visual quality check. This includes observing its size, shape, color, odor, and surface finish to ensure it is free from defects like cracks, capping, or mottling.

3.2.2 Weight Variation Test

This test ensures that each tablet contains the intended amount of drug by verifying a consistent weight across a batch. According to standard pharmacopeial methods, 20 tablets are weighed individually to calculate an average weight, and each tablet's weight is then compared against this average. The allowable percentage deviation depends on the average weight of the tablet, with stricter limits for heavier tablets^2,18.

 

 

3.2.3 Hardness (Crushing Strength)

Tablet hardness is the force required to break a tablet by applying pressure diametrically. It's an important test because if a tablet is too soft, it may break during handling or packaging, while a tablet that's too hard may not disintegrate properly, leading to poor dissolution and bioavailability. Hardness is measured using instruments such as a Monsanto or Pfizer hardness tester¹⁹.

 

 

3.2.4 Thickness and Diameter

The thickness and diameter of a tablet are measured using a Vernier caliper or micrometer. Ensuring uniform size is important for patient acceptability and for proper packaging and dispensing. These dimensions are directly influenced by the die fill and the compression force used during manufacturing.

3.2.5 Friability

Friability measures a tablet's tendency to chip or break under mechanical stress, such as in a blister pack or bottle. The test is conducted using a Roche Friabilator, where 20 tablets are tumbled for 100 revolutions¹¹. The percentage of weight loss is then calculated, with an accepted limit of less than 1% to pass the test.

 

 

3.2.6 Disintegration Test

This test determines the time it takes for a tablet to break up into small fragments in a specified liquid medium under controlled temperature conditions. The test is performed using a disintegration test apparatus. For immediate-release tablets, the disintegration time is typically less than 15 minutes, while for film-coated tablets it is less than 30 minutes. Enteric-coated tablets have a specific requirement to not disintegrate in gastric fluid but to disintegrate in intestinal fluid²⁰.

 

 

3.2.7 Dissolution Test

The dissolution test is a critical in-vitro performance test that measures the rate and extent to which the drug dissolves from the tablet into a liquid medium. This test is a key indicator of a drug's bioavailability and is essential for regulatory approval. The most common apparatus used are the

USP Type I (Basket) and Type II (Paddle)¹¹.

 

 

3.2.8 Content Uniformity

Content uniformity ensures that the active drug is evenly distributed throughout the batch and that each tablet contains the correct dose. This test involves analyzing 10 individual tablets using a validated assay method, such as HPLC or UV spectrophotometry. According to USP criteria, each unit must contain between 85-115% of the label claim, with a relative standard deviation (RSD) of 6% or less^2,21.

3.2.9 Stability Testing

Stability testing assesses a tablet's quality over time under specific environmental stress conditions, which helps determine its shelf life. Common conditions include accelerated stability studies ( 75% RH for 6 months) and long-term stability studies

(60% RH for 12-24 months)^16,19. During these studies, parameters such as appearance, assay, dissolution, hardness, and friability are monitored to ensure no significant changes occur.

 

 

 

 

Table 2: Post-Compression Tests for Tablets

Parameter	Instrument/Method	Significance	USP/IP Limit
Appearance	Visual inspection	Acceptability, compliance	Should be uniform
Weight variation	Weighing balance	Ensures dose uniformity	±5-10%
Hardness	Monsanto/Pfizer tester	Tablet strength vs. disintegration	4−10 kg/cm2
Thickness/Diameter	Vernier caliper	Uniformity in size	±5% variation allowed
Friability	Roche friabilator	Resistance to chipping	≤1%
Disintegration	Disintegration apparatus	Tablet breakdown time	≤15−30 min (depends on type)
Dissolution	USP Basket/Paddle	Drug release rate	As per monograph
Content uniformity	Assay (UV/HPLC)	Dose uniformity	85-115%
Stability	Climatic chambers	Shelf-life & storage	No significant change

 

 

 

   

 

 

   

 

Figure 3  Capsule

 

 

Figure 4 Comprehensive  Evaluation Pathway for Capsul

6. Critical Appraisal & Practical Recommendations

The systematic evaluation of tablets and capsules, while guided by pharmacopeial standards, requires a critical appraisal of their methodologies and practical application in a real-world setting. This section highlights common challenges and provides best-practice recommendations for ensuring quality and regulatory compliance.

6.1 Common Pitfalls and Challenges

Despite standardized procedures, several common issues can arise during the evaluation and manufacturing of solid oral dosage forms.

• Tablet Issues: A major pitfall in tablet manufacturing is the occurrence of capping and lamination, where layers of the tablet separate, often due to poor compression or air entrapment in the powder blend. Another common problem is an imbalance between hardness and disintegration. A tablet that is too hard may have excellent physical strength but will fail to disintegrate and dissolve properly, leading to poor bioavailability. Conversely, a tablet that is too soft will disintegrate quickly but may not withstand the stresses of handling and packaging, leading to friability issues^4,17.
• Capsule Issues: Capsules have their own unique set of challenges, particularly related to the shell.

Cross-linking and brittleness can occur in gelatin capsule shells due to improper storage conditions or interactions with certain ingredients, which can significantly affect the capsule's disintegration and dissolution profiles. Another issue is leakage in softgels, which can compromise the stability of the drug and affect the dose uniformity^10,16,22.

6.2 Best-Practice Recommendations

To overcome these challenges and ensure robust product quality, the following recommendations are advised:

• Integrated Approach: Instead of viewing evaluation tests as isolated steps, a holistic and integrated approach is essential. Pre-compression parameters, such as the flow and density indices of the powder, should be directly correlated with post-compression tests like hardness and weight variation to predict and prevent problems.
• Design of Experiments (DoE): Using a Design of Experiments (DoE) approach during formulation development allows formulators to systematically understand how different variables (e.g., compression force, excipient ratios) impact the final product's quality attributes¹². This proactive approach helps prevent many common problems before they occur, improving efficiency and reducing waste.

6.3 Conclusion Of The Section

In essence, a critical appraisal of evaluation tests moves beyond simply checking boxes for regulatory compliance. It involves understanding the complex interplay between material properties, manufacturing processes, and the final product's performance. By adopting best practices and leveraging modern technologies, pharmaceutical companies can ensure dose accuracy, consistent release, and patient safety while also enabling efficient scale-up and technology transfer.

7. Gaps & Future Directions

While the evaluation of tablets and capsules is a well-established science, several gaps and future directions in both technology and regulatory practice are shaping the future of pharmaceutical quality control. The field is rapidly moving from a traditional, batch-based testing model to a more proactive, patient-centric, and data-driven approach.

7.1 Gaps in Current Evaluation Practices

Despite the robustness of current pharmacopeial standards, some critical gaps and challenges remain:

• Reliance on Destructive Testing: Many key evaluation tests, such as friability, hardness, disintegration, and dissolution, are destructive. This means that a large number of tablets or capsules must be sacrificed from each batch, which can be inefficient and costly, particularly for high-value or low-volume products.
• Limited Biorelevance: While dissolution testing is a critical quality attribute, standard pharmacopeial dissolution media may not always accurately simulate the complex physiological conditions within the human gastrointestinal tract. Factors like pH variations, bile salts, and food intake can significantly affect drug release and absorption, leading to a gap between in-vitro and in-vivo performance.
• Excipient Variability: Excipient properties, such as flowability, compressibility, and moisture content, can vary significantly between batches and suppliers. These variations can have a profound impact on the final product's quality, but current testing methods may not be sensitive enough to detect subtle changes that can lead to manufacturing issues or product instability.
• Lack of Real-Time Monitoring: Traditional quality control is often a post-production process, where a sample from a finished batch is tested in a separate lab. This can be time-consuming and inefficient. If a problem is found, the entire batch may need to be rejected, leading to significant financial losses^10,15.

7.2 Future Directions and Innovative Solutions

The pharmaceutical industry is embracing new technologies to address these gaps and create a more efficient and reliable evaluation process.

• Integration of Process Analytical Technology (PAT): The future lies in implementing PAT to enable real-time release and quality control. This approach integrates advanced sensors and data analytics directly into the manufacturing process to monitor and control critical quality attributes as they are being produced.
• For example, NIR and Raman spectroscopy can be used in-line to continuously monitor drug content and moisture levels without destroying the product, thus ensuring uniform quality in real-time.
• Artificial Intelligence and Machine Learning: AI and machine learning are poised to revolutionize quality control. These technologies can analyze vast amounts of data from manufacturing processes and quality tests to predict potential deviations, optimize formulations, and even detect flaws in tablets, such as cracks and inconsistencies, with greater accuracy and speed than human inspection^6,15.
• Patient-Centric Formulations: The future of solid dosage forms is increasingly patient-centric. This involves developing products that are easier for patients to use, such as fast- or orally disintegrating tablets (FDT/ODT) for individuals with dysphagia. Future evaluation methods will need to be tailored to these new dosage forms, focusing on parameters like wetting time and in-mouth disintegration that are more relevant to the patient experience^7,8.
• Advanced Simulation and Modeling: Computational modeling and advanced in-silico tools will play a larger role in predicting a drug's performance in the body. This approach will reduce the need for extensive and costly in-vivo studies by simulating drug dissolution and absorption in the GI tract.
• Continuous Manufacturing: The industry is moving towards continuous manufacturing, which integrates all production steps into a single, uninterrupted process. This shift requires a new approach to quality control, moving away from batch-based testing to continuous, in-line monitoring to ensure that quality is built into the product from the very beginning^12,15.

By adopting these future-focused strategies, the pharmaceutical industry can not only enhance the quality and safety of tablets and capsules but also streamline the manufacturing process, reduce costs, and accelerate the delivery of life-saving medicines to patients.

CONCLUSION

This review has thoroughly consolidated and appraised the essential evaluation tests for solid oral dosage forms, specifically tablets and capsules. From the initial pre-compression analysis of powder blends to the final stability studies of the finished product, it is clear that a rigorous and systematic approach to quality control is the cornerstone of modern pharmaceutical manufacturing. By ensuring that every product meets established pharmacopeial and regulatory standards, manufacturers can guarantee dose accuracy, consistent drug release, and patient safety.

The enduring dominance of tablets and capsules in the global market is a testament to their inherent advantages, including patient convenience, cost-effectiveness, and stability. However, their widespread use places a critical responsibility on the industry to maintain stringent quality. The review has highlighted that while both forms share some core evaluation parameters like weight variation and content uniformity, their unique characteristics necessitate distinct testing protocols. For tablets, key tests focus on mechanical strength, such as

hardness and friability, to ensure the compressed form withstands physical stress. Conversely, capsule evaluation places a greater emphasis on shell integrity and its susceptibility to moisture, which can lead to issues like brittleness or cross-linking.

A critical takeaway from this review is that a static, post-production quality control model is no longer sufficient. The pharmaceutical landscape is rapidly evolving, with a shift towards more proactive, in-process, and real-time evaluation methods. The integration of

Process Analytical Technology (PAT), including non-destructive techniques like Near-Infrared (NIR) spectroscopy and Raman spectroscopy, represents a significant leap forward. These technologies allow for continuous monitoring of critical quality attributes, enabling a more efficient and reliable manufacturing process. Furthermore, the advancement of

in-vitro/in-vivo correlation (IVIVC) is improving our ability to predict a drug's performance in the body, which can streamline development and reduce the need for extensive in-vivo studies.

In summary, the robust evaluation of tablets and capsules is a dynamic field that balances time-honored pharmacopeial requirements with innovative technologies. The move toward continuous manufacturing, advanced data analytics, and patient-centric formulations will define the future of quality control. By embracing these advancements, the industry can not only address common pitfalls like capping in tablets and cross-linking in capsules but also ensure that pharmaceutical products are consistently safe, effective, and of the highest quality for patients worldwide.

REFERENCES

1. Indian Pharmacopoeia (IP), Government of India, Ministry of Health and Family Welfare, 2018.
2. United States Pharmacopeia (USP) 43-NF 38, The United States Pharmacopeial convention 2020.
3. Lachman, L., Lieberman, H.A., & Kanig, J.L. (1986). The Theory and Practice of Industrial Pharmacy, 3rd Edition, Varghese Publishing House.
4. Allen, L.V., Popovich, N.G., & Ansel, H.C. (2011). Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, 9th Edition, Lippincott Williams & Wilkins.
5. Sharma, P., & Jain, S. (2020). Capsule dosage forms: Evaluation and quality control tests. International Journal of Pharmaceutical Research & Sciences, 11(3), 245-258.
6. Verma, R., & Singh, S. (2018). Tablet and capsule quality evaluation: Comparative review. Journal of Pharmaceutical Sciences & Research, 10(12), 3125-3135.
7. Aulton, M.E. (2018). Aulton’s Pharmaceutics: The Design and Manufacture of Medicines, 5th Edition, Elsevier.
8. ICH Q1A(R2). Stability Testing of New Drug Substances and Products, International Conference on Harmonisation, 2003.
9. Banker, G.S., & Rhodes, C.T. (2002). Modern Pharmaceutics, 4th Edition, CRC Press.
10. Gupta, P., & Kaur, H. (2019). Moisture content and stability studies of capsules and tablets: A review. Journal of Pharmaceutical Analysis, 9(3), 175-184.
11. USP <711> Dissolution, The United States Pharmacopeial Convention, 2020.
12. Shinde, P., & Patil, R. (2019). Comparative analysis of commercial tablets and capsules: Physical and chemical parameters. Pharmaceutical Methods, 10(2), 77-89.
13. ICH Q8(R2). Pharmaceutical Development, International Conference on Harmonisation, 2009.
14. ICH Q10. Pharmaceutical Quality System, International Conference on Harmonisation, 2008.
15. Kumar, S., & Sharma, P. (2020). Innovative evaluation techniques for tablets and capsules using PAT and NIR. Journal of Pharmaceutical Sciences, 109(7), 2190-2205.
16. Singh, R., & Bansal, A. (2020). Advances in in-vitro and in-vivo correlation for solid oral dosage forms. Drug Development and Industrial Pharmacy, 46(9), 1435-1447.
17. Gennaro, A.R. (2000). Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & Wilkins.
18. Bhardwaj, S., & Sharma, M. (2021). Advances in evaluation of solid oral dosage forms. International Journal of Pharmaceutical Investigation, 11(1), 10-21.
19. Mohammed, F., & Al-Azzawi, A. (2022). Evaluation of hardness, friability, and disintegration of various tablet formulations. Journal of Pharmaceutical Innovation, 17, 245-258.
20. USP <905> Disintegration of Tablets and Capsules, The United States Pharmacopeial Convention, 2020. 11.
21. Roy, S., & Das, S. (2021). Quality control parameters and validation studies for solid oral dosage forms. International Journal of Pharmaceutical Sciences and Research, 12(8), 4120-4135.
22. Ramesh, P., & Kumar, A. (2019). Evaluation of Pharmaceutical Tablets: A Review. Journal of Drug Delivery and Therapeutics, 9(2), 134-142.
23. Banker, G.S., & Rhodes, C.T. (2002). Modern Pharmaceutics, 4th Edition, CRC Press.
24. USP <1216> Tablet Friability, The United States Pharmacopeial Convention, 2020.
25. Patel, K., & Sharma, V. (2021). Comparative study on tablet and capsule dissolution using different media. International Journal of Drug Formulation and Research, 12(4), 310-328.